Table 1.

Potential gonadal toxicity according to the American Society of Clinical Oncology (ASCO) (adapted from Pentheroudakis et al., 2010; Lambertini et al., 2016).

Degree of risk	Type of Cancer Treatment
High risk (>80% risk of permanent amenorrhea)	HSC transplantation with cyclophosphamide/TBI or cyclophosphamide/busulfan External beam radiation to a field that includes the ovaries CMF, CEF, CAF, TAC x 6 cycles in women ≥ 40 years Melphalan Chlorambucil Dacarbazine Procarbazine Ifosfamide Thiotepa Nitrogen mustard
Intermediate risk (40 % - 60 % risk of permanent amenorrhea)	BEACOPP CMF, CEF, CAF, TAC x 6 cycles in women age 30–39 AC x 4 cycles in women≥40 years AC or EC x 4 → Taxanes Anthracyclines Cisplatin Carboplatina Ara-C (Cytarabine)
Low risk (<20 % risk of permanent amenorrhea)	ABVD in women ≥32 years CHOP x 4–6 cycles CVP AML therapy (anthracycline/cytarabine) ALL therapy (multi-agent) CMF, CEF, CAF, TAC x 6 cycles in women≤30 years AC x 4 cycles in women ≤40 years Bleomycin Actinomycin D Vinca alkaloids Mercaptopurine Etoposide Fludarabine
Very low or no risk (Risk of permanent amenorrhea)	ABVD in women <32 years Methotrexate Fluorouracil Vincristine Tamoxifen
Unknown risk (Risk of permanent amenorrhea)	Monoclonal antibodies  (trastuzumab, bevacizumab, cetuximab) Tyrosine kinase inhibitors (erlotinib, imatinib) Taxanes Oxaliplatin Irinotecan

HSC: Hematopoietic stem cell; TBI: total body irradiation; CMF: cyclophosphamide, methotrexate, fluorouracil; CEF: cyclophosphamide, epirubicin, fluorouracil; CAF: cyclophosphamide, doxorubicin, fluorouracil; TAC: docetaxel, doxorubicin, cyclophosphamide; BEACOPP: doxorubicin, bleomycin, vincristine, etoposide, cyclophosphamide, procarbazine; AC: doxorubicin, cyclophosphamide; EC: epirubicin, cyclophosphamide; ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine; CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone; CVP: cyclophosphamide, vincristine, prednisone; AML: acute myeloid leukemia; ALL: acute lymphocytic leukemia.